Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):763–764. doi: 10.1038/bjc.1991.170

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.

M J Millward 1, B M Cantwell 1, M Dowsett 1, J Carmichael 1, A L Harris 1
PMCID: PMC1972372  PMID: 1903951

Full text

PDF
764

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brentani M. M., Franco E. L., Oshima C. T., Pacheco M. M. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach. Int J Cancer. 1986 Nov 15;38(5):637–642. doi: 10.1002/ijc.2910380504. [DOI] [PubMed] [Google Scholar]
  2. Bryan R. M., Mercer R. J., Bennett R. C., Rennie G. C., Lie T. H., Morgan F. J. Androgen receptors in breast cancer. Cancer. 1984 Dec 1;54(11):2436–2440. doi: 10.1002/1097-0142(19841201)54:11<2436::aid-cncr2820541121>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Attree S. L., Virdee S. S., Jeffcoate S. L. Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin Endocrinol (Oxf) 1985 Sep;23(3):303–312. doi: 10.1111/j.1365-2265.1985.tb00228.x. [DOI] [PubMed] [Google Scholar]
  4. Dowsett M., Cunningham D. C., Stein R. C., Evans S., Dehennin L., Hedley A., Coombes R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989 Mar 1;49(5):1306–1312. [PubMed] [Google Scholar]
  5. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  6. Ferguson K. M., Hayes M., Jeffcoate S. L. A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay. Ann Clin Biochem. 1982 Sep;19(Pt 5):358–361. doi: 10.1177/000456328201900507. [DOI] [PubMed] [Google Scholar]
  7. Howell A., Mackintosh J., Jones M., Redford J., Wagstaff J., Sellwood R. A. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567–1572. doi: 10.1016/0277-5379(88)90046-6. [DOI] [PubMed] [Google Scholar]
  8. Kuhn J. M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J. F., Costa P., Husson J. M., Dahan R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989 Aug 17;321(7):413–418. doi: 10.1056/NEJM198908173210701. [DOI] [PubMed] [Google Scholar]
  9. Manni A., Arafah B. M., Pearson O. H. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer. 1981 Dec 1;48(11):2507–2509. doi: 10.1002/1097-0142(19811201)48:11<2507::aid-cncr2820481127>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  10. Miller W. R., Telford J., Dixon J. M., Hawkins R. A. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol. 1985 Apr;21(4):539–542. doi: 10.1016/0277-5379(85)90049-5. [DOI] [PubMed] [Google Scholar]
  11. Moguilewsky M., Bertagna C., Hucher M. Pharmacological and clinical studies of the antiandrogen Anandron. J Steroid Biochem. 1987;27(4-6):871–875. doi: 10.1016/0022-4731(87)90162-2. [DOI] [PubMed] [Google Scholar]
  12. Perrault D. J., Logan D. M., Stewart D. J., Bramwell V. H., Paterson A. H., Eisenhauer E. A. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs. 1988 Sep;6(3):207–210. doi: 10.1007/BF00175399. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES